IVIG for sudden worsening of IPF
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a diagnosis of idiopathic pulmonary fibrosis (IPF).
- You are currently in the hospital for a sudden worsening of IPF (called an acute exacerbation) that started within the last month.
- You have not taken high doses of steroids or certain immune-suppressing drugs recently.
- You do not have active cancer, except for minor skin cancer or very early prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether simple blood tests done when you are admitted to the hospital for a sudden worsening of pulmonary fibrosis (called an acute exacerbation) can help predict how you will do. This might help doctors plan better care.
This trial tests a treatment that reduces certain antibodies in your blood, which may help slow the progression of IPF. The treatment involves a procedure to filter your blood and then giving you antibodies to help your immune system.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
This trial tests whether giving an intravenous medication called alpha-1 antitrypsin can help people who are hospitalized with a sudden worsening of COPD (called an exacerbation). The medicine may help reduce lung inflammation and improve recovery.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.